Incanthera plc (AQSE: INC), the specialist oncology company focused on innovative technologies in oncology and dermatology, confirms that the Annual Report and Accounts for the year ended 31 March 2022, and the Notice of Annual General Meeting ("AGM") with accompanying Form of Proxy has been posted to shareholders today.
These documents are also available, in electronic form, for download on the Company's website: www.incanthera.com
Incanthera's AGM will be held at 11:00 a.m. on Tuesday, 27 September 2022 at the offices of Gateley Plc, Ship Canal House, 98 King Street, Manchester, M2 4WU.
The Meeting will focus on the formal business of the meeting only.
In order to ensure that all shareholders are able to follow the proceedings of the AGM, the Company will provide access online through the Investor Meet Company platform. However, shareholders will not be able to vote online during the Meeting and are therefore urged to submit their votes via proxy as early as possible, electronically or by post.
Shareholders are also invited to submit written questions for the Board to consider. Questions can be pre submitted in advance of the AGM via the Investor Meet Company Platform up to 9.00am on 26 September 2022, being the day before the AGM, or via the Investor Meet Platform at any time during the AGM itself.
The Board will respond to key questions during the meeting and will provide such answers on its website thereafter.
Shareholders who wish to attend the AGM online should register for the event in advance via the following link:
For further enquiries:
Tim McCarthy, Chairman
+44 (0) 7831 675747
Simon Ward, Chief Executive Officer
+44 (0) 7747 625506
Suzanne Brocks, Head of Communications
+44 (0) 7776 234600
Aquis Exchange Corporate Adviser:
Cairn Financial Advisers LLP
Jo Turner/James Lewis
+44 (0) 20 7213 0880
Stanford Capital Partners Ltd
Patrick Claridge/John Howes/Bob Pountney
+44 (0) 20 3815 8880
Notes to Editors
Incanthera is a specialist oncology company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions.
The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. The company is in active discussions with Global partners for a potential licensing deal for Sol.
The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.
Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.
For more information on the Company please visit: www.incanthera.com